Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
